COMPANY PROFILE
M2BIO SCIENCES INC.
SYMBOL : WUHN
SECTOR : PSYCH.
O/S : 48 M
MARKET CAP : $ 15 M
MARKET OPPORTUNITY : UP TO $350 B
M2BIO SCIENCES INC. is the MOST UNDERVALUED company in the psychedelic market being one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals.
Psilocybin Study with University Of Pretoria, South Africa
M2BIO SCIENCES INC. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.
In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies
MAJOR DEVELOPMENT
M2BIO SCIENCES INC. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial in Psilocybin research for medical conditions such as alcohol addiction and related mental health diseases & cardiovascular conditions.
COMPANY BRIEF
| Researching and developing indications for psilocybin new therapies
| Researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands
| Currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
| Cosmetics and FSMP company with cannabinoid and psilocybin research, formulation and delivery system divisions
HIGHLIGHTS
| First in market to research psilocybin for treatment of alcoholism and cardiovascular tissue
| Established distribution channels in the US, Canada, Europe and Africa
| Early stage entry into cannabinoid and psilocybin company- Enormous upside
| Research undiscovered properties of cannabinoids for treatment of respiratory infectious diseases
M2BIO DEVELOPMENT
M2Bio ACQUISITIONS, DIVISIONS & STRATEGIC PARTNERS
WUHAN Cosmetics and food name Dr. AnnaRx
WUHAN infused beverages MEDSPRESSO CBD
WUHAN infused beverages MEDSPRESSO Mushroom
VERY SMALL FLOAT
M2BIO SCIENCES INC. O/S is ONLY 48 millions with a small float of 10 millions
M2Bio COMPARABLE
RVV | OTC
COMPANY INFORMATION
JOIN FACEBOOK INVESTOR GROUP
Wuhan last news | article
Psychedelic market: What’s coming for M2Bio Sciences in 2021 ?
OTC PINK : WUHN The CEO of M2Bio Sciences (Wuhan General Group), Jeff Robinson, provided an update on the company in an interview which has just been published. In this…
M2Bio Sciences closes Acquisition of Tsime Pharmaceuticals (PTY) Limited
CAPE TOWN, SA / ACCESSWIRE / January 14, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
M2bio Sciences (Wuhan General Group) Announces $450,000 USD Private Placement by ThreeD Capital Inc.
CAPE TOWN, SA / ACCESSWIRE / December 30, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
M2Bio Sciences, Inc (Wuhan General Group) Launches Hemp Product Research & Development Division
CAPE TOWN, SA / ACCESSWIRE / December 23, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research…
M2Bio Sciences, Inc (Wuhan General Group) Updates on Second Scientific Paper Published on Psychedelics
CAPE TOWN, SA / ACCESSWIRE / December 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
M2Bio Sciences, Inc (Wuhan General Group) Expands into UK Market with Medspresso
CAPE TOWN, SA / ACCESSWIRE / December 18, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research…
M2Bio Sciences preparing to launch a line of mushroom based health beverages into the international retail market
On December 08, 2020, M2Bio Sciences | WUHN (OTC) made an announcement that he was looking for a food scientist specializing in mushrooms for a launch a line of mushroom…
M2Bio Sciences, Inc. (Wuhan General Group) Financials Update
CAPE TOWN, SA / ACCESSWIRE / December 4, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…
A penny stock in the psychedelic market one step ahead ?
It wasn’t until early 2020 that investors started hearing about the psychedelic market. This investor enthusiasm is certainly not unrelated to the report from the Cannacord firm which estimates the…
Medspresso & Handcrafted Delights Launch Event in Cape Town | M2Bio Sciences
OTC PINK : WUHN CAPE TOWN, SA / ACCESSWIRE / November 02, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based…
M2Bio Sciences | WUHN Updates on University of Pretoria Research Collaboration for Psilocybin Magic Mushroom Clinical Trials
OTC PINK : WUHN CAPE TOWN, SA / ACCESSWIRE / October 29, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based…
Medspresso Launches Handcrafted Delights, CBD Infused Functional Foods | M2Bio Sciences (WUHN)
CAPE TOWN, SA / ACCESSWIRE / October 26, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical…